Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: A randomized trial

Annals of Internal Medicine

Volumn 149, Issue 8, 2008, Pages 531-539

  Esposito, Katherine ^a   Ciotola, Miryam ^a   Maiorino, Maria Ida ^a   Gualdiero, Roberto ^a   Schisano, Bruno ^a   Ceriello, Antonio ^b   Beneduce, Flora ^c   Feola, Giovanni ^a   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c Vico Equense/Sorrento   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; NEUTRAL PROTAMINE LISPRO INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; NEUTRAL PROTAMINE LISPRO; PROTAMINE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFECTION; ITALY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; HYPOGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PROTAMINES; SULFONYLUREA COMPOUNDS; WEIGHT GAIN;

EID: 54549107987     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-149-8-200810210-00005     Document Type: Article

References (36)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53. [PMID: 9742976]
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17. [PMID: 7587918]
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86. [PMID: 8366922]
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12. [PMID: 10938048]
5. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31 Suppl 1:S12-54. [PMID: 18165335]
6. International Diabetes Federation. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation; 2005.
7. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31:173-5. [PMID: 18165348]
8. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-12. [PMID: 10359389]
9. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20. [PMID: 14693960]
10. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43. [PMID: 17145742]
11. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-72. [PMID: 16873813]
12. Goldberg RB, Holman R, Drucker DJ. Clinical decisions. Management of type 2 diabetes. N Engl J Med. 2008;358:293-7. [PMID: 18199869]
13. Halperin F, Ingelfinger JR, McMahon GT. Clinical decisions. Management of type 2 diabetes - polling results. N Engl J Med. 2008;358:e8. [PMID: 18272888]
14. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-8. [PMID: 11118018]
15. HOE 901/300s Study Group. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130-6. [PMID: 10937510]
16. Ridde MC, Rosenstock J, Gerick JE. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-6. [PMID: 14578243]
17. Fritsche A, Schweitzer MA, Haring HU. 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138:952-9. [PMID: 12809451]
18. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442-51. [PMID: 16456680]
19. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet. 2002;41:1043-57. [PMID: 12403642]
20. Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Pract. 2001;55:177-82. [PMID: 11351771]
21. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999;130:389-96. [PMID: 10068412]
22. American Diabetes Association. Nutrition recommendation and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31:S61-78.
23. Maran A, Crepaldi C, Tiengo A, Grassi G, Vitali E, Pagano G, et al. Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care. 2002;25:347-52. [PMID: 11815508]
24. Riddle MC. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. Diabetes Care. 2008;31(Suppl 2):S125-30. [PMID: 18227472]
25. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758-67. [PMID: 11315844]
26. Statement from the ADA Related to ACCORD Trial. Accessed at www.diabetes.org/for-media/pr-ada-statement-related-to-accord-trail- announcement-020608.jsp on 21 April 2008.
27. Holman RR, Steemson J, Turner RC. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabet Med. 1987;4:457-62. [PMID: 2959438]
28. Nybäck-Nakell A, Adamson U, Lins PE, Landstedt-Hallin L. Glycaemic responsiveness to long-term insulin plus sulphonylurea therapy as assessed by sulphonylurea withdrawal. Diabet Med. 2007;24:1424-9. [PMID: 17976204]
29. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, et al. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-30. [PMID: 17890232]
30. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-74. [PMID: 16732007]
31. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, et al. INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-5. [PMID: 15677776]
32. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc. 2007;55:182-8. [PMID: 17302653]
33. McMahon GT, Dluhy RG. Intention to treat - initiating insulin and the 4-T study [Editorial]. N Engl J Med. 2007;357:1759-61. [PMID: 17890233]
34. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008;371:1073-84. [PMID: 18374840]
35. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45:937-48. [PMID: 12136392]
36. McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;30:1044-8. [PMID: 17277042]